OTC Markets EXMKT - Delayed Quote USD

GenSight Biologics S.A. (GSGTF)

Compare
0.3200 -2.7800 (-89.68%)
At close: September 20 at 4:00 PM EDT
Loading Chart for GSGTF
DELL
  • Previous Close 3.1000
  • Open 0.4800
  • Bid --
  • Ask --
  • Day's Range 0.4500 - 0.4500
  • 52 Week Range 0.0003 - 0.7550
  • Volume 756
  • Avg. Volume 3
  • Market Cap (intraday) 44.566M
  • Beta (5Y Monthly) 2.30
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6000
  • Earnings Date Sep 23, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Fran?aise contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

www.gensight-biologics.com

16

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GSGTF

View More

Performance Overview: GSGTF

Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GSGTF
31.91%
CAC 40
0.47%

1-Year Return

GSGTF
57.62%
CAC 40
4.50%

3-Year Return

GSGTF
96.58%
CAC 40
13.12%

5-Year Return

GSGTF
77.78%
CAC 40
31.93%

Compare To: GSGTF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GSGTF

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    32.49M

  • Enterprise Value

    50.67M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.98

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    35.84

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -105.83%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.96M

  • Net Income Avi to Common (ttm)

    -26.22M

  • Diluted EPS (ttm)

    -0.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.13M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.13M

Company Insights: GSGTF

People Also Watch